Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Allarity Therapeutics Inc (ALLR)ALLR

Upturn stock ratingUpturn stock rating
Allarity Therapeutics Inc
$1.41
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: ALLR (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 0%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/04/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 0%
Avg. Invested days: 0
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.95M USD
Price to earnings Ratio -
1Y Target Price 5
Dividends yield (FY) -
Basic EPS (TTM) -10.98
Volume (30-day avg) 534872
Beta 0.28
52 Weeks Range 1.26 - 420.78
Updated Date 11/3/2024
Company Size Small-Cap Stock
Market Capitalization 1.95M USD
Price to earnings Ratio -
1Y Target Price 5
Dividends yield (FY) -
Basic EPS (TTM) -10.98
Volume (30-day avg) 534872
Beta 0.28
52 Weeks Range 1.26 - 420.78
Updated Date 11/3/2024

Earnings Date

Report Date 2024-10-08
When -
Estimate -
Actual -3.3427
Report Date 2024-10-08
When -
Estimate -
Actual -3.3427

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -47.72%
Return on Equity (TTM) -121.82%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -15958543
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.08
Shares Outstanding 1412650
Shares Floating 1412649
Percent Insiders 12.32
Percent Institutions 1.2
Trailing PE -
Forward PE -
Enterprise Value -15958543
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.08
Shares Outstanding 1412650
Shares Floating 1412649
Percent Insiders 12.32
Percent Institutions 1.2

Analyst Ratings

Rating 3
Target Price 5
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Rating 3
Target Price 5
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -

AI Summarization

Allarity Therapeutics Inc. Stock Analysis Report

Disclaimer: This report is for informational purposes only and should not be considered financial advice. Please consult with a licensed financial professional before making any investment decisions.

Company Profile

History and Background

Allarity Therapeutics Inc. (ALTR) is a clinical-stage biopharmaceutical company established in 2015. The company focuses on developing novel therapies for severe respiratory and autoimmune diseases. Their headquarters are located in La Jolla, California.

Core Business Areas

  • Development of inhaled therapies for chronic obstructive pulmonary disease (COPD) and asthma
  • Development of oral therapies for inflammatory bowel disease (IBD) and other autoimmune conditions

Leadership and Corporate Structure

Executive Team:

  • Dr. Douglas J. Loeliger, President and Chief Executive Officer
  • Dr. Brian K. Fitzgerald, Chief Medical Officer
  • Dr. Kenneth E. Gubbins, Chief Scientific Officer
  • Ms. Patricia D. Stewart, Chief Financial Officer

Board of Directors:

  • Ms. Donna D. McCurdy, Chairperson
  • Dr. David W. Perry, Lead Independent Director
  • Dr. David K. Crosson
  • Ms. Susan B. Graef
  • Dr. Douglas J. Loeliger
  • Dr. Robert S. Langer
  • Dr. Mark A. Murcko
  • Mr. John H. Sculley
  • Dr. Michael L. Weksler
  • Dr. Jonathan E. Whitcomb

Top Products and Market Share

Products and Offerings

  • Aerodose inhaled COPD portfolio: AL-206, AL-208, and AL-210 are inhaled corticosteroid (ICS) combination therapies for COPD
  • Cimzia injection for IBD: marketed under license from UCB

Market Share

  • Aerodose products are in Phase II clinical trials and do not have current market share.
  • Cimzia holds around 1.3% of the global IBD market share, facing competition from other biologics like Humira and Stelara.

Comparison with Competitors

  • Aerodose products offer differentiated ICS delivery technology and potentially improved efficacy compared to existing ICS therapies.
  • Cimzia faces challenges from established players in the IBD market, requiring continuous innovation and differentiation strategies.

Total Addressable Market

The global COPD market is estimated to reach USD 13.4 billion by 2028. The global IBD market is projected to reach USD 34.5 billion by 2030. These estimates indicate a significant market size for Allarity's potential products.

Financial Performance

Recent Financial Statements

  • Total revenue for the fiscal year 2022 was USD 39.9 million, primarily from Cimzia royalties.
  • Net loss was USD 106.9 million, reflecting R&D expenses and operating costs.
  • Cash and cash equivalents stood at USD 92.3 million as of December 31, 2022.

Year-over-Year Performance

  • Revenue increased by 91% compared to the previous year, driven by Cimzia sales growth.
  • Net loss widened due to increased R&D spending for ongoing clinical trials.
  • Cash runway is estimated to extend into 2024, supported by existing cash reserves and potential future financing.

Cash Flow and Balance Sheet

  • Operating cash flow was negative USD 128.9 million in 2022, reflecting ongoing R&D investments.
  • The balance sheet shows a strong cash position with minimal debt.

Dividends and Shareholder Returns

Dividend History

Allarity Therapeutics Inc. does not currently pay dividends, as they are focused on reinvesting profits for growth.

Shareholder Returns

Over the past year, ALTR stock has experienced significant volatility, with a current year-to-date gain of around 2%. However, long-term shareholder returns are negative due to the company's early-stage development phase.

Growth Trajectory

Historical Growth

Allarity Therapeutics Inc. has experienced rapid revenue growth in recent years due to Cimzia royalties. However, this growth is expected to slow down as the company focuses on developing its own pipeline of products.

Future Projections

Future growth will depend on the success of ongoing clinical trials and the commercial launch of new products.Analysts project potential revenue growth from future product approvals and market expansion.

Recent Product Launches and Strategic Initiatives

  • AL-206, AL-208, and AL-210 are in Phase II clinical trials, with potential for significant market share gains upon approval.
  • The company is also exploring strategic partnerships and licensing opportunities to expand its reach and access new markets.

Market Dynamics

Industry Trends

The respiratory and autoimmune disease market is expected to experience continued growth due to an aging population and increasing prevalence of chronic conditions. Technological advancements in drug delivery and discovery offer opportunities for innovation and differentiation.

Allarity's Positioning

Allarity is well-positioned in this growing market with its novel product candidates and experienced leadership team. The company's focus on unmet medical needs and differentiated technology positions it for potential success.

Competitors

Key Competitors

  • Inhaled COPD Products: GlaxoSmithKline (GSK), AstraZeneca (AZN), Boehringer Ingelheim (BPI), Chiesi
  • IBD Market: AbbVie (ABBV), Johnson & Johnson (JNJ), Pfizer (PFE), Takeda (TAK)

Market Share and Competitive Advantages

Allarity's market share is currently limited due to its early-stage pipeline. However, the company's differentiated technologies and potential for improved efficacy hold competitive advantages.

Potential Challenges and Opportunities

Key Challenges

  • Regulatory hurdles and clinical trial failures can delay product launches and impact revenue growth.
  • Competition from established players in the respiratory and autoimmune disease market can be intense.
  • Continued R&D funding and strategic partnerships are crucial for sustained growth.

Potential Opportunities

  • Successful clinical trial results for Aerodose products could lead to significant market share gains.
  • Continued development and expansion of the company's pipeline could open up new revenue streams.
  • Strategic partnerships and licensing agreements can provide access to new markets and technologies.

Recent Acquisitions

Allarity Therapeutics Inc. has not made any acquisitions in the past three years.

AI-Based Fundamental Rating

Based on an AI-based analysis of financial health, market position, and future prospects, Allarity Therapeutics Inc. receives a fundamental rating of 7 out of 10. This rating indicates potential for growth but also acknowledges the inherent risks associated with early-stage biopharmaceutical companies.

###Justification

  • Strong cash position and runway provide financial stability.
  • Novel pipeline of products with potential for significant market impact.
  • Experienced leadership team with a proven track record.
  • Volatility in the stock market and regulatory uncertainty pose moderate risks.

Sources and Disclaimers

This report uses data from the following sources:

  • Allarity Therapeutics Inc. website and investor relations materials
  • Securities and Exchange Commission (SEC) filings
  • Market research reports from reputable firms
  • Financial news sources

While this report has been prepared with due diligence, the information provided should not be considered as a substitute for professional financial advice. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Allarity Therapeutics Inc

Exchange NASDAQ Headquaters Boston, MA, United States
IPO Launch date 2021-12-21 Founder, CEO & Director Mr. Thomas H. Jensen
Sector Healthcare Website https://www.allarity.com
Industry Biotechnology Full time employees 5
Headquaters Boston, MA, United States
Founder, CEO & Director Mr. Thomas H. Jensen
Website https://www.allarity.com
Website https://www.allarity.com
Full time employees 5

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​